Systemic inflammatory response index (SIRI) predicts poor survival in pancreatic cancer patients treated with FOLFIRINOX

Kamposioras, K.; Razzaq, M.; Ahmad, U.; Damyanova, I.; Papaxoinis, George

doi:10.1093/annonc/mdz155.165

Cited by 4 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The systemic inflammatory response index (SIRI) is a combined marker of systemic inflammation, exclusively used to assess prognosis and therapeutic response in various cancers [ 19 ]. SIRI, described for the study of cancer-related inflammation [ 19 ], is based on peripheral neutrophil, monocyte and lymphocyte [ 20 ]. This is the first study, to our knowledge, that assesses this ratio in a non-malignant inflammatory situation and in acute biliary pancreatitis.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of Prognostic Factors of Severity in Acute Biliary Pancreatitis

Silva-Vaz

Abrantes

Castelo‐Branco

et al. 2020

IJMS

View full text Add to dashboard Cite

Acute pancreatitis (AP) is an inflammatory disorder of the pancreas that, when classified as severe, is associated with high morbidity and mortality. Promptly identifying the severity of AP is of extreme importance for improving clinical outcomes. The aim of this study was to compare the prognostic value of serological biomarkers, ratios, and multifactorial scores in patients with acute biliary pancreatitis and to identify the best predictors. In this observational and prospective study, the biomarkers, ratios and multifactorial scores were evaluated on admission and at 48 h of the symptom onset. On admission, regarding the AP severity, the white blood count (WBC) and neutrophil–lymphocyte ratio (NLR), and regarding the mortality, the WBC and the modified Marshall score (MMS) showed the best predictive values. At 48 h, regarding the AP severity, the hepcidin, NLR, systemic inflammatory response index (SIRI) and MMS and regarding the mortality, the NLR, hepcidin and the bedside index for severity in AP (BISAP) score, showed the best predictive values. The present study enabled the identification, for the first time, of SIRI as a new prognostic tool for AP severity, and validated hepcidin and the NLR as better prognostic markers than C-reactive protein (CRP) at 48 h of symptom onset.

show abstract

Section: Introductionmentioning

confidence: 99%

Evaluation of Prognostic Factors of Severity in Acute Biliary Pancreatitis

Silva-Vaz

Abrantes

Castelo‐Branco

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…SIRI, an innovative biomarker that considerably correlates with systemic inflammation, appears to have a more potent and consistent prognostic benefit in some cancer types. 34 , 35 , 36 …”

Section: Discussionmentioning

confidence: 99%

“…Although each of the SII, NLR, LMR, PLR, PNI, and Alb indexes confers a vital prognostic impact in various malignancies. SIRI, an innovative biomarker that considerably correlates with systemic inflammation, appears to have a more potent and consistent prognostic benefit in some cancer types 34–36 …”

Section: Discussionmentioning

confidence: 99%

“…SIRI, an innovative biomarker that considerably correlates with systemic inflammation, appears to have a more potent and consistent prognostic benefit in some cancer types. [34][35][36] SIRI concurrently integrates all three cells (neutrophils, lymphocytes, and monocytes) extracted from serum and, thereby, allows better assessment of inflammatory responses associated with tumorigenesis and progression. Likewise, contrasted with single-cell components, the consolidated SIRI is less likely to be affected in diverse clinical settings: infections, impaired liver function, fluid retention, and dehydration.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Prognosis and complications of patients with primary gastrointestinal diffuse large B‐cell lymphoma: Development and validation of the systemic inflammation response index‐covered score

et al. 2023

View full text Add to dashboard Cite

Background This study aimed to evaluate the predictive value of systemic inflammation response index (SIRI) in primary gastrointestinal diffuse large B‐cell lymphoma (PGI‐DLBCL) patients and establish a highly discriminating risk prediction model. Methods This retrospective analysis included 153 PGI‐DCBCL patients diagnosed between 2011 and 2021. These patients were divided into a training set ( n = 102) and a validation set ( n = 51). Univariate and multivariate Cox regression analyses were conducted to examine the significance of variables on overall survival (OS) and progression‐free survival (PFS). An inflammation‐covered score system was established according to the multivariate results. Results The presence of high pretreatment SIRI (≥1.34, p < 0.001) was significantly associated with poorer survival and identified as an independent prognostic factor. Compared with NCCN‐IPI, the prognostic and discriminatory capability of the novel model SIRI‐PI showed a more precise high‐risk assessment with a higher area under the curve (AUC) (0.916 vs 0.835) and C ‐index (0.912 vs 0.836) for OS in the training cohort, and similar results were obtained in the validation cohort. Moreover, SIRI‐PI also showed good discriminative power for efficacy assessment. This new model identified patients at risk of developing severe gastrointestinal complications following chemotherapy. Conclusions The results of this analysis suggested that the pretreatment SIRI may be a potential candidate for identifying patients with a poor prognosis. And we established and validated a better‐performing clinical model, which facilitated the prognostic stratification of PGI‐DLBCL patients and can serve as a reference for clinical decision‐making.

show abstract

“…Many studies have indicated that systemic inflammation and nutritional status, such as the systemic inflammation response index (SIRI), neutrophil to lymphocyte ratio (NLR), platelet-to lymphocyte-ratio (PLR) and prognostic nutritional index (PNI), were associated with the survival of many malignancies (20)(21)(22)(23), including pancreatic cancer (24)(25)(26)(27). These markers are promising predictors of clinical prognosis of cancer because they are inexpensive and easy to estimate.…”

Section: Introductionmentioning

confidence: 99%

Efficacy of stereotactic body radiation therapy for locoregional recurrent pancreatic cancer after radical resection

Zhou²,

Ding³

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

ObjectiveThis study aimed to analyze the efficacy and toxicity of stereotactic body radiotherapy (SBRT) for locoregional recurrent pancreatic cancer after radical resection.MethodsPatients with locoregional recurrent pancreatic cancer after surgery treated with SBRT in our institution were retrospectively investigated from January 2010 to January 2020. Absolute neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) recorded at pretreatment were analyzed. Endpoints included overall survival (OS), progression-free survival (PFS) and cumulative incidences of local failure (LF) and metastatic failure (MF).ResultsA total of 22 patients received SBRT with a median prescribed dose of 40 Gy (range of 30-50 Gy)/4 to 7 fractions. The median OS of all patients was 13.6 months (95% CI, 9.6-17.5 months). 0-1 performance status (HR 12.10, 95% CI 2.04-71.81, P=0.006) and ≤2.1 pre-SBRT NLR (HR 4.05, 95% CI 1.21-13.59, P=0.023) were significant predictors of higher OS on multivariable analysis. The median progression-free survival (PFS) of the cohort was 7.5 months (95% CI, 6.5-8.5 months). The median time to LF and MF were 15.6 months and 6.4 months, respectively. The rate of MF as a first event was higher than that of first event LF. Pain relief was observed in all patients (100%) 6 weeks after SBRT. In terms of acute toxicity, grade 1 including fatigue (6, 27.3%), anorexia (6, 27.3%), nausea (4, 18.2%) and leukopenia (4, 18.2%) was often observed. No acute toxicity of grade 4 or 5 was observed. In terms of late toxicity, no treatment-related toxicity was found during follow-up.ConclusionThis study showed that SBRT can significantly reduce pain, effectively control local tumor progression, and have acceptable toxicity for patients with locoregional recurrence after radical resection of primary pancreatic cancer. Good performance status and lower pre-SBRT NLR were associated with improved overall survival.

show abstract

Systemic inflammatory response index (SIRI) predicts poor survival in pancreatic cancer patients treated with FOLFIRINOX

Cited by 4 publications

References 0 publications

Evaluation of Prognostic Factors of Severity in Acute Biliary Pancreatitis

Evaluation of Prognostic Factors of Severity in Acute Biliary Pancreatitis

Prognosis and complications of patients with primary gastrointestinal diffuse large B‐cell lymphoma: Development and validation of the systemic inflammation response index‐covered score

Efficacy of stereotactic body radiation therapy for locoregional recurrent pancreatic cancer after radical resection

Contact Info

Product

Resources

About